Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04099290 · ClinicalTrials.gov registry record
Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
A clinical trial of Carcinoma, Squamous Cell and Head and Neck Neoplasm, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT04099290 is a study of Carcinoma, Squamous Cell and Head and Neck Neoplasm that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 50 participants, below the 257-participant average among 14 other Carcinoma, Squamous Cell trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04099290, a study of Carcinoma, Squamous Cell and Head and Neck Neoplasm, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Circulating tumor DNA (ctDNA) is a blood-based test that measures dying or dead cancer cells that are already circulating in the blood. In this study, the investigators will enroll patients who are planning to receive surgery to remove their head and neck cancer. The investigators are interested to learn how ctDNA levels change with surgery and over the course of time. The investigators also want to determine if there are certain features of the tumor or the patient themselves that might cause ctDNA to be higher than other patients. Also, the investigators want to explore if the detection of ctDNA following surgery is related to cancer recurrence.
Conditions Studied
Interventions
- OTHER Blood and tumor samples
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-01-14 |
| Est. Completion | 2027-02-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04099290
The ClinicalTrials.gov registry entry for NCT04099290 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 14 other Carcinoma, Squamous Cell trials with a reported enrollment target (81% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Carcinoma, Squamous Cell appearing as the primary indexed condition, and to 1 intervention - of which Blood and tumor samples is the first listed.
NCT04099290 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04099290 about?
NCT04099290 is a clinical study titled "Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma". Circulating tumor DNA (ctDNA) is a blood-based test that measures dying or dead cancer cells that are already circulating in the blood. In this study, the investigators will enroll patients who are planning to receive surgery to remove their head and neck cancer. The investigators are interested to ...
What is the current status of trial NCT04099290?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2020-01-14. Estimated completion is 2027-02-01.
What conditions does trial NCT04099290 study?
This clinical trial studies the following conditions: Carcinoma, Squamous Cell, Head and Neck Neoplasm.
What interventions are being tested in trial NCT04099290?
The interventions under investigation include: Blood and tumor samples (OTHER).
Who is sponsoring clinical trial NCT04099290?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04099290 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Squamous Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
RECRUITING · Phase 1
-
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
RECRUITING · Phase 1
-
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
RECRUITING
-
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
RECRUITING · Phase 2
-
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RECRUITING · Phase 1
-
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.